RICHMOND, VA., April 30 /CNW/ - Insmed Inc., (Nasdaq:INSM) today
announced positive results from a Phase II investigator-sponsored clinical
study of the company's drug IPLEX(TM) in HIV-infected patients affected with
HIV-associated Adipose Redistribution Syndrome (HARS).
